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Purpose: Over the past 30 years, the incidence of melanoma has been climbing at a 
faster rate than any other malignancy. In 2019, it is projected that close to 100,000 new 
patients will be diagnosed with melanoma. Melanoma would then become the fifth 
most common type of cancer in the United States.1 With the advent of anti-PD-1 
immunotherapies, such as pembrolizumab and nivolumab, an individual’s own 
immune system can now recognize and kill cancers, such as melanoma2. 
Immunotherapies bring a new and exciting approach to the treatment of melanoma 
and other forms of cancer. A review of the current state of clinical studies in the setting 
of metastatic melanoma treatment is therefore needed to understand better how 
progression-free survival and overall survival have been effected with the introduction 
of anti-PD-1 antibodies.    
Materials and Methods: Five clinical research trials were selected for review based on 
the following criteria: use of either pembrolizumab or nivolumab as a monotherapy for 
patients with metastatic melanoma. The progression-free survival period and overall 
survival were determined and, where appropriate, compared to chemotherapy or the 
cytotoxic T-lymphocyte antigen-4 inhibitor, ipilimumab. 
Results: Across the five clinical studies, pembrolizumab and nivolumab showed 
statistically significant improvement in progression-free survival and overall survival in 
three out of five studies. The two studies that did not find a statistical significance still 
showed a numerical improvement   
Conclusion: Pembrolizumab and nivolumab, given as monotherapy, improve 
progression-free survival and overall survival when compared to chemotherapies and 








Skin cancer is the most common cancer diagnosed in the United States; however, 
cutaneous melanoma only accounts for less than 5% of all skin cancers1,3. Globally, 
melanoma is the 19th most common cancer with an incidence rate of 2.8-3.1 per 
100,0004. Men are more likely to be diagnosed with melanoma than women, with a 
lifetime risk of 1 in 37 and 1 in 56, respectfully. Interestingly, there is a significant 
variation in incidence between countries. Australia has the highest incidence of 37 per 
100,000, whereas South-Central Asia has one of the lowest incidence rates of 0.2 per 
100,0005.  The incidence of melanoma in the United States is 22 per 100,0006. In 2019, 
studies project that there will be 96,480 new melanomas diagnosed in the United 
States. Melanoma will, therefore, be the 5th most common type of cancer after breast, 
lung, prostate, and colorectal cancers6.  
 Unfortunately, for the past 30 years, the incidence of melanoma has been 
climbing at a faster rate than any other malignancy1,5. Numerous risk factors may 
increase the incidence of melanoma. Risk factors include, but are not limited to, 1) fair-
skinned, freckling, and light hair, as those with a fair complexion are by far the most at 
risk for melanoma, with melanoma being 20 times more common in whites than African 
Americans7; 2) ultraviolet (UV) light exposure, as melanomas of the trunk, back, and 
legs have been linked to repeated sunburns caused by the damaging UV rays from the 
sun or tanning beds7; 3) family history, as the risk of developing melanoma is higher 
among individuals whose first-degree relative(s) were diagnosed with melanoma, and 
10% of all patients diagnosed with melanoma have a family history of the disease7; and 
4) immunosuppression, as individuals with a weakened immune system from diseases 
such as HIV or medical treatments such as chemotherapy are more likely to develop 




 Within the last 15 years, there has been an increased understanding of the 
genetic mutations associated with melanoma. Two of the most researched and 
understood melanoma mutations involve the BRAF and NRAS oncogenes. Research 
determined that activating mutations in both of these oncogenes promote 
downstream signaling changes that ultimately lead to an enhancement of tumor 
growth and a promotion of disease progression.8 The most common activating 
mutation of the BRAF oncogene, the V600E, is the substitution from valine (V) to 
glutamic acid (E) in codon 600 of exon 15 and accounts for approximately 90% of all 
BRAF mutations.8,9 An NRAS activating mutation is seen in 15-25% of melanomas and 




Melanoma falls into four primary subcategories: 1) superficial spreading melanoma 
(SSM), 2) nodular melanoma (NM), 3) lentigo maligna melanoma (LMM), and 4) acral 
lentiginous melanoma (ALM). SSM is the most common subtype in the United States, 
accounting for over 70% of diagnosed melanoma10. SSM most commonly presents as 
a macule or a thin plaque with an irregular border and can range anywhere from a few 
millimeters to several centimeters in diameter. As the name suggests, SSM begins in 
situ and may or may not become invasive11. 
 Nodular melanoma accounts for 15-30% of all melanomas10. The nodular type 
typically presents as a plaque or nodule that may be pedunculated with dark 
pigmentation. Unlike other subtypes of melanoma, NM more commonly presents with 
symmetric borders, uniform color, and a smaller diameter. This presentation makes the 
nodular subtype much more challenging to diagnose in the early stages. While the 




mm, the NM subtype is more often diagnosed at a thickness of 2mm or greater12. NM 
is the most rapidly growing and most aggressive form of melanoma11.  
 Lentigo maligna melanoma accounts for 10-15% of melanomas and is another 
in situ melanoma10. LMM is associated with sun-damaged skin in the elderly and fair-
skinned individuals. LMM typically starts as a tan macule that is irregular in shape. The 
macule will spread peripherally and will develop multiple shades of a brown and tan 
color. LMM is slow-growing and can grow for up to 15 years before becoming 
invasive13.   
 Acral lentiginous melanoma accounts for <5% of all melanomas and is a 
melanoma that forms in situ before becoming invasive10. Unlike the other subtypes of 
melanoma, ALM commonly presents as a dark black-brown discoloration on the soles 
of the feet, palms of the hands, and the skin under the nails. Interestingly, ALM is the 
most common melanoma diagnosed in African Americans and Asians and the least 
common among Caucasians14. 
 Advanced melanoma, also known as metastatic melanoma, is any subtype of 
melanoma that has spread from the primary tumor site to other organs in the body. A 
classification system, called the “TNM classification," is the recognized standard for 
classifying the extent of the spread of many types of cancers, including melanoma. “T” 
stands for primary tumor and is rated on a scale of T1 to T4. “N” stands for regional 
lymph nodes and is rated N0 through N3. “M” stands for distant metastasis and is rated 








Table 1: TNM classification of melanoma.  
 
Melanoma progression goes through 5 different stages (stage 0 through 5), and the 
TNM classification relates clinical findings to the different stages of the disease (see 
table 4 in the appendix). Stage 0, while not cancerous, does mean that abnormal cells 
are present in situ, but they have not spread to nearby tissue. Stage I is correlated with 
T1 to T2 (without ulceration), N0, and M0. The melanoma has not spread to nearby 
tissue and is considered to be in its early stages. Stage II correlates with T2 (with 
ulceration) to T4, N0, and M0. Stage III correlates to any T value, N >1, and M0. Stage 
IV correlates to any T, any N, and M greater than or equal to 1.   
 In addition to staging a melanoma, patients will be given a performance status. 
The most widely used performance status is the Eastern Cooperative Oncology Group 
(ECOG) performance status15. The ECOG performance status is particularly useful 
when planning or conducting clinical trials as it can be used as a standard for clinical 






































the definition of a population of patients to be studied15. Patients are rated on a scale 
of 0-5. Zero represents a patient who is fully active without restriction, and five 
represents a patient who has died (see table 2).   
 





Several additive characteristics determine the natural course of melanoma. These 
characteristics include overall metastatic spread, overall thickness of the tumor, 
localization, ulceration, and histological subtype of the primary tumor16. It is well 
documented that melanoma develops via three metastatic pathways: 1) satellite or in-
transit metastasis, 2) regional lymph node metastasis, or 3) directly distant metastasis16.  
Satellite metastases are defined as the occurrence of metastatic nodules within two 
centimeters of the primary tumor, while in-transit metastases refer to the lymphatic 
system and are defined as the development of metastasis within the dermal/subdermal 
lymphatic area prior to the first regional lymph node17. Regional lymph nodes are 
defined as a spread from the local area into the lymphatic system. Directly distant 




lymph nodes18. There is limited research into the pattern of metastatic melanoma 
pathways; however, in a 2017 study, 50% of patients with metastatic melanoma 
developed regional lymph nodes, while 28% and 22% developed distant metastases 
and satellite or in-transit metastases, respectively17. The most up to date guidelines 
show that the current five year survival rate for metastatic melanoma is 50%, up from 




Before the development of targeted therapies and immunotherapies, chemotherapy 
was given for the treatment of advanced melanoma. Dacarbazine and temozolomide 
were the most common chemotherapy drugs that were used20. These chemotherapies 
can be used alone or in combination with other therapies such as carboplatin or 
taxanes. Although chemotherapy is no longer the first treatment of choice, it continues 
to play an important role in the treatment of metastatic melanoma. Chemotherapy can 
be used in the treatment of patients that lack the mutations that current targeted 
therapies use, or it can be used as salvage therapy after a patient progresses on first-
line and second-line treatments20.  
 Targeted therapies and immunotherapies are now considered first-line 
treatment for metastatic melanoma. Targeted therapies included vemurafenib and 
dabrafenib. These targeted therapies inhibit mutated BRAF proteins, which stops cell 
proliferation and prevent cell survival21. Other targeted therapies such as trametinib 
inhibit proteins further downstream from the BRAF protein with a similar goal of 
preventing cell proliferation.21 Immunotherapies such as ipilimumab, pembrolizumab, 
and nivolumab interact with our own immune system, allowing for the identification 
and destruction of cancer cells. Ipilimumab works by blocking the CTLA-4 protein 




protein to “turn off” the immune system and thus avoid detection. By blocking CTLA-4 
with ipilimumab, the cancer cells become detectable and are destroyed by the immune 
system2. Pembrolizumab and nivolumab are immunotherapies that target the PD-
1/PD-L1 pathway. As a way of avoiding the T-cells of the immune system, cancer cells 
will display the PD-L1 protein on their surface, which acts like a "shield," protecting the 
cancer cells from the immune system2. Pembrolizumab and nivolumab are antibodies 
that bind to the PD-1 protein on the surface of T-cells, preventing the PD-L1 protein on 
the cancer cells from binding, which allows the cancer cells to be detected and 












The FDA has approved several new treatment options for metastatic melanoma. Some 
of the most promising new therapies are immunotherapies, such as pembrolizumab 
and nivolumab. The goal of this narrative review is to assess if patients with metastatic 
melanoma treated with pembrolizumab or nivolumab have improved progression-free 





A systematic literature review was done on July 7, 2019, using the following databases: 
PubMed, Embase, and Cochrane Library.  
 
• The search terms used in the advanced search builder for PubMed were:  
Line 1: ((advanced[tiab] OR metastatic[tiab]) AND (("melanoma"[MeSH Terms] OR 
"melanoma"[All Fields]) OR ("melanoma"[MeSH Terms] OR "melanoma"[All Fields] OR 
"melanomas"[All Fields]))).  
Line 2: (pembrolizumab[tw] OR keytruda[tw] OR Nivolumab[tw] OR opdivo[tw] OR anti-
PD 1[tiab]) 
Line 3: survival[tiab] 
Line 4: #1 AND #2 AND #3 
Line 5: #4 AND ((Meta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR 
Review[ptyp] OR systematic[sb]) AND English[lang]) 
 




 Line 1: (pembrolizumab OR keytruda OR Nivolumab OR opdivo OR anti-PD 
1):ab,ti,de 
 Line 2: ((advanced OR metastatic) NEAR/3 (melanoma OR melanomas)) 
 Line 3: survival:ab,ti,de 
 Line 4: #1 AND #2 AND #3 AND ([cochrane review]/lim OR [systematic 
review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized 




All articles were screened using the following criteria:  
a) all articles must be published or translated to English;  
b) given that Anti-PD-1 therapy is a relatively new treatment for metastatic 
melanoma, all articles across time are included; 
c) all patients must be over 18;  
d) all race and genders were included; 
e) all patients have been diagnosed with advanced metastatic melanoma (grade III 
or IV),  
f) prior systemic therapy was permitted, but all patients had to be treatment naïve 
to both Nivolumab and/or Pembrolizumab and stopped all prior therapy prior 
to starting anti-PD-1 therapy;  
g) all histological subtypes were included, metastatic disease to the CNS was 
permitted; 
h) nivolumab or pembrolizumab was to be given as monotherapy (no combination 
of other systemic therapy, radiotherapy, or surgical intervention);  




j) intervention including dosing regime and duration of treatment had to be 
clearly defined; 




The Modified Cochrane Collaboration Tool was used to assess for bias in this review. 
Bias is determined by judgment, either high, low, or unclear, for five individual 
domains: selection, performance, attrition, reporting, and other. Domains considered 
include 1) Random Sequence generation: If treatment groups were allocated, is it likely 
that the treatment groups were comparable? 2) Allocation concealment: if applicable, 
a judgment will be made regarding methods by which the allocation sequence was 
concealed. 3) Selective reporting: will address selective outcome reporting and how 
the authors examined this. 4) Other sources of bias: Any bias the author/s feel may have 
been of concern that is not addressed elsewhere in the study. 5) Blinding of 
participants and personnel to treatment: if applicable, will provide information on the 
steps taken to conceal treatment allocations to the participant and/or study personnel. 
The studies’ authors may address if the blinding process was effective and if it worked 
in the way that they had hoped. 6) Blinding outcome assessments: if applicable, will 
discuss the measures used to blind outcome assessors as to which intervention a 
participant received. 7) Incomplete outcome data: will assess how the authors 







The combined search of the above-listed databases produced 854 articles. After 
duplicates were screened for and removed, a total of 424 articles remained. All 424 
articles' titles and abstracts were screened for relevance on the topic matter. Of the 
424 screened studies, 375 articles were not relevant or did not treat metastatic 
melanoma specifically. Of the 49 articles that were selected for full-text review, five 
articles met eligibility based on the criteria listed above. These five studies are 
discussed in detail in this review. A summary of the findings can be found in table 2, 
and a reference to the 44 excluded articles can be found in Appendix B.   





Ascierto et al22 (CHECKMATE-066), conducted by the Istituto Nazionale Tumori 
Fondazione Pascale and funded by Bristol-Myers Squibb, is a randomized, controlled, 
double-blind phase 3 clinical trial comparing nivolumab with dacarbazine in patients 
with previously untreated stage III and IV melanoma. A total of 418 patients were 
enrolled between January 2013 and February 2014. Eligible patients were 18 years 
and older with confirmed stage III or IV melanoma and treatment naïve. An eligible 
patient must also be without a BRAF mutation and have an Eastern Group Performance 
(ECOG) status of 0 or 115.  Patients enrolled in this study were randomly assigned 1:1. 
Two-hundred and eight patients received dacarbazine 1000 mg/m2 every three weeks 
with a nivolumab-matched placebo every 2 weeks, and 210 patients revived nivolumab 
3 mg/kg every two weeks with a dacarbazine-matched placebo every three weeks. The 
primary outcome for this phase 3 study was overall survival.  Other outcomes included 
progression-free survival and tumor PD-L1 expression as a predictive biomarker of 
overall survival. Of the 208 patients randomized to receive dacarbazine, 205 were 
treated. The median progression-free survival was 2.2 months (95% CI, 2.1-2.5 
months), and the median overall survival rate was 11.2 months (95% CI, 9.6-13 months). 
Of the 210 patients that were randomized to receive nivolumab, 206 patients received 
treatment. The median progression-free survival was 5.1 months (95% CI, 3.5-12.2 
months), and the median overall survival rate was 37.5 months (95% CI, 25.5-not yet 
reached). This phase three study has demonstrated that, at the 3-year follow-up point, 
there is both an increase in progression-free survival and a durable overall survival for 
patients treated with nivolumab alone when compared to patients that have been 
treated with dacarbazine alone.  
Using the Cochrane Risk of bias tool, this study has a low risk of bias. Several 
limitations were noted in this study. There was a higher percentage of patients with an 




vs. the dacarbazine arm (58%), which may contribute to the increased overall survival 
of the nivolumab arm. In addition, patients from both groups pursued subsequent 
therapy after progression, which will likely affect the overall survival outcomes. Finally, 
per the study protocol, patients could remain on nivolumab beyond progression if it 
were deemed that they were receiving clinical benefit from the drug. Continuing on 
treatment beyond progression may again have affected the overall survival outcomes. 
 
Hamid et al23 (KEYNOTE-002), conducted by The Angeles Clinic and Research Institute 
and funded by Merck Sharp & Dohme, is a randomized phase 2 clinical trial comparing 
two doses of pembrolizumab to an investigator-choice of chemotherapy in patients 
with advanced melanoma. A total of 540 patients were enrolled from November 2012 
to November 2013. Eligible patients were 18 years and older and must have had 
confirmed disease progression no more than 24-weeks after receiving greater than 1 
dose of ipilimumab. If the patient was known to have a BRAFV600 mutation, they had to 
have had prior treatment with a MEK or BRAF inhibitor or both. Patients must also have 
an Eastern Group Performance (ECOG) status of 0 or 115, and all ipilimumab-related 
adverse events must not be greater than grade 1. Patients enrolled in this study were 
randomly assigned 1:1:1 with 180 patients received pembrolizumab 2 mg/kg every 
three weeks, 181 patients received pembrolizumab 10 mg/kg every three weeks, and 
179 patients received investigator choice of therapy. The co-primary outcomes for this 
phase 2 study were overall survival and progression-free survival. For the patients that 
were randomized to receive chemotherapy, the estimated progression-free survival 
was 0.6% (95% CI, 0.1-3.2%), and the median overall survival was 11.0 months (95% CI, 
8.9-13.8). For the patients that were randomized to receive pembrolizumab 2 mg/kg, 
the estimated progression-free survival was 16% (95% CI, 10.9-22.1%), and the median 




randomized to receive pembrolizumab 10 mg/kg, the estimated progression-free 
survival was 22% (95% CI, 16.1-28.3%), and the median overall survival was 14.7 
months (95% CI, 11.3-19.5). Although this phase 2 study was able to show that there 
was a numerical improvement in overall survival for patients receiving pembrolizumab, 
there was not a statistically significant improvement. There was no significant 
difference in efficacy between the two doses of pembrolizumab, which is consistent 
with findings from other studies such as KEYNOTE -001 and KEYNOTE 006.  
Using the Cochrane Risk of bias tool, this study has a low risk of bias. Several 
limitations have been noted in this study. At the time of data cut-off, no patients were 
receiving chemotherapy. Fifty-five percent of the patients randomized to receive 
chemotherapy had crossed over to the pembrolizumab arm, perhaps contributing to 
a decreased ability to calculate overall survival for the chemotherapy arm. The authors 
of the study concluded that the lack of overall survival benefit is not surprising and 
contributed it to the overall demanding statistical crossover design of the study.  
 
Hamid et al24 (KEYNOTE-001), conducted by The Angeles Clinic and Research 
Institute and funded by Merck Sharp & Dohme, is an open-label, phase 1b clinical trial 
comparing three different doses of pembrolizumab. A total of 655 patients were 
enrolled between December 2011 and September 2013. Eligible patients were 18 
years old and with documented stage III and stage IV melanoma. Prior treatment was 
not required, but if a patient did receive treatment, their last dose must be no less than 
4 weeks prior to the first dose of pembrolizumab and have no prior history of being 
treated with anti-PD-1/PD-L1 therapies. Patients must also have an Eastern Group 
Performance (ECOG) status of 0 or 115. Patients were enrolled in nonrandomized and 
randomized cohorts. Of the 655 patients enrolled, 151 were treatment naïve, and 496 




overall survival of all patients against treatment-naïve patients. At the time of data cut-
off, 63% of all patients and 54% of treatment-naïve patients had died. For all patients, 
the median progression-free survival was 8.3 months (95% CI, 5.8-11.1), and the 
median overall survival rate was 23.8 months (95% CI, 20.2-30.4). For treatment-naïve 
patients, the median progression-free survival was 16.9 months (95% CI, 9.3-35.5), and 
the median overall survival rate was 38.6 months (95% CI, 27.2-NR). This study was 
successful at presenting the first long-term follow-up data from a clinical trial of 
pembrolizumab. There was a significant improvement in both progression-free survival 
and overall survival in the treatment-naïve group. These findings suggest that 
pembrolizumab has the greatest benefit when given as first-line therapy. However, 
even for patients that have received prior treatment, receiving pembrolizumab has 
shown to give a significant benefit24.  
Using the Cochrane Risk of bias tool, this study has an unclear risk of bias. 
Limitations noted in this study include the exclusion of analyzing progression-free 
survival and overall survival among the groups that received different doses of 
pembrolizumab. The study also compared all patients against patients that were 
treatment-naïve. It is unclear as to why the study authors decided to present that data 
this way, as patients that were treatment naïve would have also been included in the 
'all-patients' group making the comparison blurred. Also, the study’s authors did not 
mention in their results how many patients received additional treatments after 
progression in this study. If patients on either arm of the study were further treated with 
another antitumor drug, then this would influence overall survival times reported in this 
study.   
 
Larkin et al25 (CHECKMATE-037), conducted and funded by Bristol-Myers Squibb, is a 




chemotherapy of the investigator's choice in patients with advanced melanoma. A total 
of 405 patients were enrolled from December 2012 to January 2014. Eligible patients 
were 18 years or older, had progressed on prior antitumor treatment, had documented 
stage III or IV metastatic melanoma, and had an Eastern Group Performance (ECOG) 
status of 0 or 115. Patients were excluded from the trial if they had active brain 
metastases, or had prior treatment with any PD-1 or PD-L1 therapy.  For the purposes 
of this clinical trial, the patients were stratified by PD-L1 expression, BRAF status, and 
best response to prior CTLA-4 therapy. Patients enrolled in this study were randomly 
assigned 2 (nivolumab): 1 (investigator’s choice). Two-hundred sixty-eight patients 
were randomized to receive IV nivolumab 3 mg/kg every 2 weeks. One-hundred two 
patients were randomized to receive the investigator’s choice of chemotherapy (ICC), 
which consisted of dacarbazine 1,000 mg/m2 every 3 weeks, or carboplatin area under 
the curve 6 plus paclitaxel 175 mg/m2 every 3 weeks. The CHECKMATE-037 study had 
two primary endpoints. These endpoints were progression-free survival and overall 
survival when comparing nivolumab against the investigator's choice of 
chemotherapy. For the patients that were randomized to receive the investigator's 
choice of chemotherapy, the progression-free survival was 3.7 months (95% CI, 2.3-
5.3), and the median overall survival was 14.4 months (95% CI, 11.7- 18.2). For the 
patients that were randomized to receive nivolumab, the progression-free survival was 
3.1 months (95% CI, 2.3-3.5), and the median overall survival was 15.7 months (95% CI, 
12.9-19.9).  
Using the Cochrane Risk of bias tool, this study has a low risk of bias. The 
CHECKMATE-037 clinical trial showed that there is a slight improvement in overall 
survival for patients that received nivolumab; however, their findings were not 
statistically significant. Although there is no difference in survival benefit between 




caution. Although the risk of bias was overall low, there were several factors that the 
study’s authors concluded may have had an impact on overall survival. Important 
factors included the open-label design of the study (which allowed patients on the ICC 
arm to receive nivolumab after progression), poor prognosis (patients with brain 
metastases, and elevated LDH were at a higher ratio in the nivolumab arm), and high 
patient drop out in the ICC arm. All the mentioned factors may have led to a bias of 
healthier patients in the ICC arm, and because of this bias, there was no significant 
difference in survival time between the two treatments. 
   
Schachter et al26 (KEYNOTE-006) conducted by the Sheba Medical Center and funded 
by Merck & Co., is an open-label, randomized, phase 3 clinical trial comparing two 
different doses of pembrolizumab against ipilimumab in patients with confirmed stage 
III and IV melanoma. Between September 2013 and March 2014, a total of 811 patients 
were enrolled and treated per the study’s protocol. Eligible patients were 18 years and 
older with confirmed stage III or IV melanoma. Patients were allowed to have had up 
to 1 previous systemic therapy (excluding pembrolizumab, nivolumab, and 
ipilimumab), and must have an Eastern Group Performance (ECOG) status of 0 or 115. 
Patients were excluded if they had active brain metastases or active autoimmune 
disease requiring systemic steroid treatment. Patients enrolled in this study were 
randomly assigned 1:1:1. Two hundred seventy-eight patients revived pembrolizumab 
10 mg/kg every 2 weeks, two hundred seventy seven patients received 
pembrolizumab 10 mg/kg every three weeks, and two hundred fifty six patients 
received ipilimumab 3 mg/kg every three weeks. The primary outcomes of this study 
included progression-free survival and overall survival. For the patients that received 
pembrolizumab 10 mg/kg Q2weeks, the median progression-free survival was 5.6 




not yet reached). For the patients that received pembrolizumab 10 mg/kg Q3weeks, 
the median progression-free survival was 4.1 (range 2.9-2.7), and the overall survival 
had not yet been reached (range 23.5- not yet reached). For the patients that received 
ipilimumab, the median progression-free survival was 2.8 months (range 2.8-2.9), and 
the median overall survival was 16.0 months (range 13.5-22.0). KEYNOTE-006 was the 
first of its kind to do a direct comparison study of pembrolizumab against ipilimumab.  
Using the Cochrane Risk of bias tool, this study has a low risk of bias. KEYNOTE-
006 findings show that there are significant improvements in progression-free survival 
and overall survival for the patients that received pembrolizumab when compared to 
ipilimumab. However, drawing conclusions from this study's findings should be done 
with caution.  Specific limitations in this clinical trial may have had a significant impact 
on overall survival. For patients that were on the ipilimumab arm, more than half went 
on to receive further anticancer treatment, of which 30% went on to receive anti-PD-1 
therapy. This additional care may artificially elevate the overall survival rating of study 


































































































































































































































The aim of this narrative review was to assess the ongoing research into 
pembrolizumab and nivolumab for the treatment of metastatic melanoma. Historically, 
cytotoxic chemotherapies were used as a treatment for metastatic melanoma. But with 
the development of newer systemic treatment regimens, such as targeted therapy and 
immunotherapy, the use of chemotherapy is now considered third or fourth-line 
therapy. In specific patient populations, cytotoxic chemotherapy has been omitted 
altogether27.  
The current findings from clinical trials show that pembrolizumab and nivolumab 
are providing significant improvements in progression-free survival and overall 
survival. As seen in the CHECKMATE-066 study, nivolumab as a first-line treatment for 
BRAF wild-type melanomas provided longer progression-free survival times as well as 
a durable response leading to significant overall survival benefit when compared to 
the chemotherapy dacarbazine. Additionally, the KEYNOTE-006 study showed that 
pembrolizumab (as a monotherapy) was superior to the immunotherapy ipilimumab 
(as a monotherapy).  
Interestingly, both the KEYNOTE-002 and the CHECKMATE-037 clinical trials 
made a head-to-head comparison of pembrolizumab and nivolumab, respectfully, 
against the investigator's choice of chemotherapy. Patients in both studies had 
progressed on prior systemic therapy before being enrolled in the trails. Specifically, 
patients in the KEYNOTE-002 had to have advanced on ipilimumab before enrolling in 
the study. The results from KEYNOTE-002 showed a numerical improvement for 
patients that received pembrolizumab over chemotherapy but failed to show a 
significant difference. The CHECKMATE-037 had similar results to the KEYNOTE-002 




survival. However, CHECKMATE-037 (like KEYNOTE-002) failed to show statistical 
significance. The results from both KEYNOTE-002 and CHECKMATE-037 provide 
evidence that the use of immunotherapy after prior systemic treatment does not 
provide the same benefits compared to patients that are treatment naïve. It is worth 
noting that both studies had significant limitations (discussed in the results section of 
this review) that may have affected the final overall survival analysis. Any conclusions 
from these studies should be drawn with caution; however, it does lead the way for 
newer studies to assess microenvironment changes in tumors that leads to an impaired 
response to pembrolizumab and nivolumab.  
Increasing the dosage or decreasing the interval between infusions of 
pembrolizumab or nivolumab did not have a significant improvement in the responses 
measured. In the KEYNOTE-002 study, study patients received either pembrolizumab 
2 mg/kg or 10 mg/kg every three weeks. There was no significant difference between 
the dosing groups. These results were further confirmed by the KEYNOTE-001 study, 
which compared pembrolizumab 2 mg/kg and 10 mg/kg every three weeks and 10 
mg/kg every two weeks and the KEYNOTE-006 study which compared pembrolizumab 
10 mg/kg every two weeks and three weeks.  
It is important to note that throughout all the studies reviewed, progression-free 
survival and overall survival is reported in months and not in years. For studies that 
could show a significant benefit in using pembrolizumab and nivolumab, the 
differences in survival were as small as 2 months. For patients that are facing a terminal 
diagnosis, the prospect of a treatment providing an additional few months to disease 
progression is preferred. It should also be noted that this review focused on 
immunotherapies given as monotherapies. Studies that have combined 
immunotherapies have shown that up to 50% of patients with metastatic melanoma 




Although it is not discussed in this review, the side effect profile of 
immunotherapies is much less when compared to chemotherapy. For example, a 2016 
study used health-related quality of life analysis to compare quality for survival in 
patients that received nivolumab vs. chemotherapy (dacarbazine).28 The study found 
that nivolumab had a better long-term quality of survival benefit when compared to 
dacarbazine. However, it is important to note the common side effects (immune-
related side effects) of immunotherapies. Patients taking either pembrolizumab or 
nivolumab will commonly experience diarrhea (17% and 19% respectfully), pruritus 
(14% and 19% respectfully), fatigue (21% and 34% respectfully).29 The side effect 
profile and expected symptoms are a key considerations when discussing the patient's 
quality of life while on treatment. The targeted nature, the increase in survival, and the 
lower side effect profile is what makes immunotherapies the standard of care for a 
patient with metastatic melanoma and shows that progress is being made in the fight 
against metastatic melanoma.  
Finally, as with any treatment that is prescribed to a patient, the cost must always 
be considered. An interesting European study done in 2018, found that cost is closely 
correlated to the overall survival time.30 The same study found that when accounting 
for the new targeted therapies and immunotherapies, the cost of metastatic melanoma 
now reaches €269,682 ($299,562) per patient. The amount an individual patient will 
pay versus the insurance company is variable and depends on the type of insurance 
the patient has, out of pocket expenses, etc. As a simple cost comparison, in November 
of 2019, 1 dose of dacarbazine (chemotherapy) cost $23-$3731, whereas 1 dose of 
pembrolizumab (immunotherapy) costs $5,010.47-$10,011.44 (depending on the 







Pembrolizumab and nivolumab continue to show significant superiority over traditional 
chemotherapies in the treatment of metastatic melanoma. With improved progression-
free survival and overall survival, anti-PD-1 therapies should be considered standard of 
care and first-line therapy for metastatic melanoma, which is consistent with current 
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The following studies were excluded because the study did not address progression 
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